Literature DB >> 2324494

Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation.

R D Granstein1, R Staszewski, T L Knisely, E Zeira, R Nazareno, M Latina, D M Albert.   

Abstract

The anterior chamber of the eye is an immunologically privileged site in which allografts survive longer than at other body sites. In this regard, it is relevant that aqueous humor (AH) inhibits lymphocyte proliferation. In order to analyze AH for specific substances that inhibit thymocyte proliferation, samples of human AH, murine AH, and rhesus monkey AH were added to cultures of thymocytes stimulated by IL-1 or IL-2 in the presence of PHA. All samples of AH tested had potent inhibitory activity on thymocyte proliferation in this system. Inhibitory activity was lost by heating AH to 80 degrees C for 1 h. Dialysis of murine AH indicated that species smaller than 3500 Da were capable of mediating this activity; we have termed the factor(s) responsible for this "small inhibitory factor(s) of AH." Retentate, containing species larger than 3500 Da, retained inhibitory activity, but less than nondialyzed AH. Assays for PGE2 demonstrated that murine and human AH contained small quantities of PGE2. These quantities were insufficient to inhibit thymocyte proliferation in our assay system. Furthermore, AH from mice treatend with indomethacin had full inhibitory activity. Assays for transforming growth factor beta (TGF-beta) after acid activation demonstrated significant quantities of latent TGF-beta within human and murine AH which could be largely neutralized by antisera to TGF-beta. Active TGF-beta "activity" was also present without acid activation in samples of AH at a level approximately 20% that of latent TGF-beta. However, most of this "activity" could not be neutralized by antisera to TGF-beta. AH contains factors capable of limiting thymocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324494

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  Sympathetic ophthalmia: an autoimmune ocular inflammatory disease.

Authors:  C C Chan; M Mochizuki
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Immunologic privilege of the eye.

Authors:  J W Streilein
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction.

Authors:  M Ueta; M-N Kweon; Y Sano; C Sotozono; J Yamada; N Koizumi; H Kiyono; S Kinoshita
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 4.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  A free-radical hypothesis for the instability and evolution of genotype and phenotype in vitro.

Authors:  R E Parchment; K Natarajan
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

6.  Primary Open-Angle Glaucoma: A Transforming Growth Factor-β Pathway-Mediated Disease.

Authors:  Andrew W Taylor
Journal:  Am J Pathol       Date:  2012-04-21       Impact factor: 4.307

Review 7.  Corneal wound healing.

Authors:  Steven E Wilson
Journal:  Exp Eye Res       Date:  2020-06-15       Impact factor: 3.467

8.  Anterior chamber-associated immune deviation-inducing cells activate T cells, and rescue them from antigen-induced apoptosis.

Authors:  M Takeuchi; P Alard; D Verbik; B Ksander; J W Streilein
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

9.  Retinal laser burn disrupts immune privilege in the eye.

Authors:  Hong Qiao; Kenyatta Lucas; Joan Stein-Streilein
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 10.  Cell signaling pathways in vertebrate lens regeneration.

Authors:  Jonathan J Henry; Alvin G Thomas; Paul W Hamilton; Lisa Moore; Kimberly J Perry
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.